Valuation: Arcutis Biotherapeutics, Inc.

Market Cap 4B 3.58B 3.31B 2.99B 5.61B 380B 5.7B 39.8B 15.74B 199B 15.01B 14.69B 630B P/E 2026 *
80.5x
P/E 2027 * 24.8x
Enterprise Value 3.71B 3.32B 3.07B 2.78B 5.2B 353B 5.29B 36.93B 14.61B 185B 13.92B 13.63B 585B EV / Sales 2026 *
6.89x
EV / Sales 2027 * 4.83x
Free-Float
98.23%
Yield 2026 *
-
Yield 2027 * -
1 day+1.96%
1 week-0.25%
Current month+20.36%
1 month+18.16%
3 months+16.31%
6 months+36.76%
Current year+9.54%
1 week 30.91
Extreme 30.91
32.94
1 month 23.37
Extreme 23.37
33.3
Current year 19.3
Extreme 19.295
33.3
1 year 19.3
Extreme 19.295
33.3
3 years 1.76
Extreme 1.76
33.3
5 years 1.76
Extreme 1.76
33.3
10 years 1.76
Extreme 1.76
40.88
Manager TitleAgeSince
Chief Executive Officer 58 01/04/2017
Corporate Officer/Principal 71 03/12/2025
Director of Finance/CFO - 15/05/2025
Director TitleAgeSince
Chairman 55 01/12/2019
Director/Board Member 58 01/01/2016
Director/Board Member 74 01/08/2020
Date Insider Type Main position Quantity % Market Cap. Importance
9/16/26 A Sell

General Counsel

-3,674 0.0029%
9/15/26 A Exercice

Director

12,922 0.0103%
9/8/26 A Sell

General Counsel

-9,989 0.0079%
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%-0.25%+58.18%+1,242.19% 4B
+0.45%+3.13%+54.96%+125.16% 1,140B
+0.94%+4.93%+39.86%+78.72% 641B
+0.39%+1.44%+25.77%+97.48% 507B
+0.10%+1.69%+48.28%+66.77% 383B
-3.21%-2.10%+60.72%+33.22% 347B
+0.75%+2.28%+25.42%+54.47% 293B
-0.14%+1.89%+2.47%+26.99% 266B
+1.22%+4.63%+52.40%+64.85% 240B
+1.70%+3.67%+31.21%+102.15% 197B
Average +0.57%+2.61%+39.93%+189.20% 401.78B
Weighted average by Cap. +0.31%+2.98%+41.79%+85.48%

Financials

2026 *2027 *
Net sales 539M 482M 446M 403M 755M 51.24B 767M 5.36B 2.12B 26.8B 2.02B 1.98B 84.86B 696M 622M 576M 521M 975M 66.19B 991M 6.93B 2.74B 34.62B 2.61B 2.56B 110B
Net income 53.19M 47.57M 44.01M 39.84M 74.57M 5.06B 75.8M 530M 209M 2.65B 200M 195M 8.38B 173M 155M 143M 130M 243M 16.5B 247M 1.73B 683M 8.63B 651M 637M 27.32B
Net Debt -288M -258M -239M -216M -404M -27.44B -411M -2.87B -1.14B -14.35B -1.08B -1.06B -45.44B -638M -570M -528M -478M -894M -60.68B -909M -6.35B -2.51B -31.74B -2.39B -2.34B -100B
Projected Income Statement - Annual - Arcutis Biotherapeutics, Inc.
Logo Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.
Employees
354
Date Price Change Volume
26/10/26 $31.81 +1.96% 1,547,906
23/10/26 $31.20 -3.11% 1,894,086
22/10/26 $32.20 +1.04% 2,075,750
21/10/26 $31.87 -2.89% 1,688,764
20/10/26 $32.82 +2.92% 4,490,710
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Arcutis Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
31.81USD
Average target price
39.12USD
Spread / Average Target
+23.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Arcutis Biotherapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ARQT Stock